Clinical trials: Chronic Hepatitis B Virus
Hepatitis B, Chronic
EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection
The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.
- Trial name
- NCT03320616
- Testing
- EYP001a
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Enyo Pharma
Hepatitis B, Chronic
A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
This is a prospective observational study of CHB patients who have not received antiviral treatment but HBV DNA are positive.Investigators aim to explore the antiviral effect and influencing factors of patients over 30 years old…
- Conditions
- Hepatitis B, Chronic, Treatment
- Trial name
- NCT07637214
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
HBV
Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
This is a retrospective prospective, open-label, multicenter clinical study aiming to recruit 400 individuals with a family history of liver cancer to explore the clinical cure rate and the effectiveness, feasibility, and safety…
- Trial name
- NCT06746701
- Testing
- Peg-IFNα-2b combined with NA, Nucleotide Analogues
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- Xiangya Hospital of Central South University
Chronic Hepatitis B
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
The purpose of this early access protocol is to provide access to adefovir dipivoxil prior to its commercial availability to people with lamivudine-resistant chronic hepatitis B who have limited treatment options.
- Trial name
- NCT00042393
- Testing
- Adefovir Dipivoxil
- Sponsor
- Gilead Sciences
Chronic Hepatitis B Infection
Hepatitis B Infection Surveillance
France is a low-endemicity country for hepatitis B virus (HBV) infection. In 2016, the prevalence of chronic HBV infection in the general population was estimated at 0.3%, corresponding to more than 135,000 HBsAg-positive…
- Trial name
- HEPB-SURVEY (NCT07727187)
- Where
- France
- Volunteers
- 1,360 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Hepatitis B
HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance
This study proposes to compare the effect of 48 weeks exposure to pegylated interferon alpha vs. nucleoside analogue (NA) on hepatitis B e antigen (HBeAg) seroconversion and HBsAg levels in nucleoside analogue controlled…
- Trial name
- NCT01769833
- Testing
- PEG-interferon-Alfa-2A, Nucleosides
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Pusan National University Hospital
Hepatitis B
Studies of Immune Responses in Patients With Chronic Hepatitis B
Taiwan is a hyperendemic area of hepatitis B virus (HBV) infection. Previous studies demonstrated vigorous T cell responses to HBV-encoded antigens developed in patients with self-limited acute hepatitis B.
- Trial name
- NCT00155155
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Hepatitis B, Chronic
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B
This is a prospective, multicentre observational study of Chronic Hepatitis B （CHB）in different clinical stages. We intend to compare the immune status of various types of CHB patients, and we propose to establish a staging and…
- Trial name
- NCT06525909
- Where
- 5 sites in China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Hepatitis B, Chronic
Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue
The purpose of this study is to evaluate the efficacy and safety of GSK548470 administered once daily at a dose level of 300 mg to Japanese patients with compensated chronic hepatitis B untreated with any nucleic acid analogue.
- Trial name
- NCT01480284
- Testing
- GSK548470 300 mg tablet, ETV 0.5 mg capsule
- Where
- 32 sites in Japan
- Volunteers
- 166 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
- Trial name
- B-Focus (NCT06497504)
- Testing
- Bepirovirsen
- Where
- 51 sites in United States, Argentina and 8 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients
The most important method to slow down and stop the liver disease progression in patients with chronic hepatitis B is antiviral therapy, by which to achieve maintaining viral response during treatment or obtain sustained viral…
- Trial name
- NCT02387684
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B Virus (HBV)
The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical Harms
The goal of this qualitative study is to explore the impact of antiviral treatment, or none, for chronic hepatitis B virus on the non-clinical (social) harms experienced by migrant populations living in the UK.
- Trial name
- B-SOCIAL (NCT07053449)
- Volunteers
- 30 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Chronic Hepatitis B
Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients
This is a Phase IV, open-label, single-arm, 96 week community-based observational study evaluating the antiviral efficacy, safety, and tolerability of TDF in HBV mono-infected Asian-American adults who had completed 48 week…
- Trial name
- NCT01267162
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Medical Procare PLLC
Chronic Hepatitis B
A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B
The purpose of this study is to evaluate the safety and tolerability of JNJ-440 in healthy and Chronic Hepatitis B (CHB) participants after single and multiple doses; and to evaluate the pharmacokinetic (PK) of JNJ-440 in healthy…
- Trial name
- NCT03439488
- Testing
- JNJ-440
- Where
- 7 sites in Moldova, New Zealand and 3 more
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatitis B, Chronic
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
REP 9AC (REP 2055) is a nucleic acid polymer (NAP) with entry and post-entry antiviral activity against duck hepatitis B virus (DHBV) infection.
- Trial name
- NCT02646189
- Testing
- REP 2139-Ca, Zadaxin, Pegasys
- Where
- Bangladesh
- Volunteers
- 12 people
- Sponsor
- Replicor Inc.
Hepatitis B, Acute-On-Chronic Liver Failure
RL-1 Novel Human-derived Bio-artificial Liver Treatment in Patients of HBV Related ACLF
This study is to investigate the clinical efficacy and safety of RL-1 Novel Human-derived Bio-artificial Liver treatment in patients with Hepatitis b virus related acute-on-chronic liver failure.
- Trial name
- NCT04195282
- Testing
- Plasma exchange, RL-1 Novel Human-derived Bio-artificial Liver Treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253
This study will evaluate immune responses in patients with HBeAg-negative chronic Hepatitis B treated with Pegasys (peginterferon alfa-2a).
- Trial name
- NCT01237496
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 5 sites in Italy
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study)
Hepatitis B virus (HBV) remains a major global health problem with an estimated 257 million people living with the infection worldwide. Chronic HBV (CHB) is a major cause of liver cirrhosis and hepatocellular carcinoma.
- Trial name
- SAMBA (NCT06668727)
- Testing
- HepB mAb19
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Aarhus University Hospital
Hepatitis B, Chronic
Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B:
The objective of this study is to identify immunological mechanisms that contribute to normalization of liver inflammation in chronic hepatitis B (CHB) patients starting the antiviral nucleoside analogue, Tenofovir alafenamide…
- Trial name
- NCT04070079
- Testing
- Tenofovir Alafenamide
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Hepatitis B, Hepatitis, Viral
A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
This is a Phase 2, open-label,randomized, multiple dose, varied administration regimen study with 2 parts (Parts A and B) in Subjects Infected with Chronic Hepatitis B Virus
- Trial name
- ACHIEVE (NCT02751996)
- Testing
- SB 9200, Tenofovir
- Where
- 17 sites in Canada, Hong Kong and 2 more
- Volunteers
- 80 people
- Sponsor
- F-star Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.